HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents.

Abstract
Cancer is a common malignant disease with complex signaling networks, which means it is unmanageable to cancer therapy by using single classical targeted drug. Recently, dual- or multitarget drugs have emerged as a promising option for cancer therapies. Although many multifunctional compounds targeting HDAC have been validated, as far as we know, there is no molecule targeting GLP and HDAC synchronously. In the present work, we designed and synthesized a series of quinazoline-based hydroxamic acid derivatives as dual GLP and HDAC inhibitors. These hybrid compounds showed potent enzymatic inhibitory activities against GLP and HDAC1/6 with IC50 values in the nanomolar range of less than 190 nM. Furthermore, most of our compounds displayed significant broad spectrum cytotoxic activities apart from D3 and D8 against all the tested cancer cells with IC50 values less than 50 μM. D1, D6 and D7 showed more potent cytotoxic activities than D2, D4 and D5 in those cancer cells. Especially, compound D7 showed potent inhibitory potency activity against both GLP and HDAC1/6 with IC50 values of 1.3, 89, 13 nM. Besides, D7 exhibited the most potent antiproliferative activity against all the tested cancer cells. Further evaluations indicated that D7 could inhibit the methylation and deacetylation of H3K9 on protein level. Moreover, D7 could induce cancer cell apoptosis, G0/G1 cell cycle arrest, and partly block migration and invasion. All these thorough evaluations warranted D7 as a promising lead compound worth further optimization and development for cancer therapy.
AuthorsHaoting Zheng, Qiuzi Dai, Zigao Yuan, Tingting Fan, Cunlong Zhang, Zijian Liu, Bizhu Chu, Qinsheng Sun, Yan Chen, Yuyang Jiang
JournalBioorganic & medicinal chemistry (Bioorg Med Chem) Vol. 53 Pg. 116524 (01 01 2022) ISSN: 1464-3391 [Electronic] England
PMID34847495 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2021 Elsevier Ltd. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Histone Deacetylase Inhibitors
  • Histones
  • Hydroxamic Acids
  • Quinazolines
  • Histone Deacetylases
Topics
  • Antineoplastic Agents (chemical synthesis, chemistry, pharmacology)
  • Cell Cycle Checkpoints (drug effects)
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Dose-Response Relationship, Drug
  • Drug Screening Assays, Antitumor
  • Histone Deacetylase Inhibitors (chemical synthesis, chemistry, pharmacology)
  • Histone Deacetylases (metabolism)
  • Histones (antagonists & inhibitors, metabolism)
  • Humans
  • Hydroxamic Acids (chemistry, pharmacology)
  • Methylation (drug effects)
  • Molecular Structure
  • Quinazolines (chemistry, pharmacology)
  • Structure-Activity Relationship
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: